Inotrem expands Series B

Paris-based Inotrem S.A., which specializes in immunotherapy for acute and chronic inflammatory syndromes, has expanded its Series B funding to 58 million euros.

Paris-based Inotrem S.A., which specializes in immunotherapy for acute and chronic inflammatory syndromes, has expanded its Series B funding to 58 million euros. Inotrem’s investors include Fountain Healthcare Partners, Kreos Capital and Bpifrance.

Source: Press Release